Detection of Human Leukocyte Antigen Class I Loss of Heterozygosity in Solid Tumor Types by Next-generation DNA Sequencing

Society for Immunotherapy of Cancer 2019

Nov 06, 2019
Oncology
Presentation

Jason Perera, Brandon Mapes, Denise Lau, Ameen Salahudeen, and Aly A. Khan

Human leukocyte antigen (HLA) class I proteins are expressed on the surface of all nucleated cells and are vital for immune surveillance. When tumor-specific mutations (neoantigens) are presented on HLA molecules to CD8+ T cells, this recognition can drive immune responses against the tumor and lead to tumor destruction. One mechanism of immune escape for tumors is loss of heterozygosity in HLA genes (HLA-LOH), which reduces the total number of neoantigens available for presentation to T cells. Due to the highly polymorphic nature of HLA, the copy number status of HLA genes is extremely challenging to assess by standard bioinformatics approaches. To investigate the prevalence of HLA-LOH, we developed a specialized pipeline to detect HLA-LOH by DNA next-generation sequencing (NGS).